Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial.

ABSTRACT:

Background

Recent findings on the benefits of glibenclamide as a neuroprotective drug have started a new era for prospective studies on sulfonylureas. The effect of glibenclamide blocking the Sur1-Trpm4 channel was examined in models of subarachnoid hemorrhage and stroke, with findings of significantly reduced tight-junction abnormalities, resulting in less edema formation and considerably reduced transsynaptic apoptosis of hippocampal neurons and significantly ameliorated impairments in spatial learning. Based on these data, we plan a clinical trial to establish evidence of glibenclamide as an adjunct treatment in aneurysmal subarachnoid hemorrhage.

Methods

An estimated 80 patients meeting the inclusion criteria of radiological confirmatory evidence of an aneurysmal subarac

SUBMITTER: da Costa BBS 

PROVIDER: S-EPMC6617901 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature